|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Calistoga Pharmaceuticals Announces Positive Clinical Results from Ongoing Single-Agent and Combination Trials of CAL-101 in Patients with Hematologic Malignancies
12/6/2010 10:17:20 AM
SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated data from an ongoing single-agent trial and the first data from a combination trial of CAL-101, the company’s oral, delta-isoform-selective PI3K inhibitor. These clinical results demonstrate the clinical potential of CAL-101, as a single agent and in combination with other standard-of-care therapies, as treatment for patients with hematologic malignancies that have relapsed or are refractory to existing treatments. In addition, pharmacokinetic data and preclinical data characterizing the pharmacological properties of CAL-101 were presented, adding to the growing body of evidence regarding CAL-101’s antitumor effects. The findings were presented during oral and poster presentations at the 52nd American Society of Hematology Annual Meeting in Orlando, FL.
|
|
|
|
|
|
|
|
|
|
|